ONC201 is an oral, first-in-class small molecule with demonstrated antitumor activity in preclinical models of difficult-to-treat solid and liquid tumors. ONC201 acts on dopamine receptors in the body to trigger a variety of known anti-cancer pathways without imparting significant toxicity. This is a Phase 1/2 open-label study of ONC201 administered orally once every week incombination with dexamethasone to patients with relapsed/refractory multiple myeloma.
The following criteria is a partial list of reasons why patients may or may not be eligible to participate in this clinical trial. Further evaluation with a medical professional will be required to determine full eligibility.
The following criteria is provided for health care professionals.